Top

Published in:

Open Access 01-06-2019 | Kidney Cancer | Clinical Trial Report

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial

Authors: Bas D. Koster, Saskia J. A. M. Santegoets, Jorien Harting, Arnold Baars, S. Marieke van Ham, Rik J. Scheper, Erik Hooijberg, Tanja D. de Gruijl, Alfons J. M. van den Eertwegh

Published in: Cancer Immunology, Immunotherapy | Issue 6/2019

Excerpt

Up until the last decade, the treatment options for metastatic renal cell carcinoma (mRCC) patients were limited. mRCC is resistant to systemic cytotoxic chemotherapy [1] and cytokine-based therapies like IFN-α and IL-2 resulted in modest response rates and little survival benefit [2]. Over the past decade, the treatment of mRCC has changed considerably with the introduction of targeted therapies and, more recently, immune checkpoint inhibitors (ICI) [3]. Although the introduction of targeted therapies has markedly improved patient outcome, they rarely induce complete responses, and most patients eventually develop resistance to these therapies. Clinical trials with ICI nivolumab (anti PD-1) and ipilimumab (anti CTLA-4) in mRCC reconfirmed the relative tractability of this tumor type to immunotherapy. However, the objective response rate of mRCC patients who received combination treatment of nivolumab and ipilimumab is still only 42% and comes at the cost of substantial (although often manageable) toxicity [4]. Therefore, further exploration of immunotherapeutic combination approaches is warranted for the treatment of mRCC. …

Available only for authorised users

Yagoda A, Bander NH (1989) Failure of cytotoxic chemotherapy, 1983–1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44:338–345. https://doi.org/10.1159/000281537 CrossRefPubMed

Coppin C, Porzsolt F, Autenrieth M et al (2004) Immunotherapy for advanced renal cell cancer. In: Coppin C (ed) Cochrane database of systematic reviews. Wiley, Chichester, p CD001425

Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH (2017) New treatment options for metastatic renal cell carcinoma. ESMO Open 2:e000185. https://doi.org/10.1136/esmoopen-2017-000185 CrossRefPubMedPubMedCentral

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290. https://doi.org/10.1056/NEJMoa1712126 CrossRefPubMedPubMedCentral

Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74. https://doi.org/10.1126/science.aaa4971 CrossRefPubMed

Keenan BP, Jaffee EM (2012) Whole cell vaccines–past progress and future strategies. Semin Oncol 39:276–286. https://doi.org/10.1053/j.seminoncol.2012.02.007 CrossRefPubMedPubMedCentral

McCune CS, O’Donnell RW, Marquis DM, Sahasrabudhe DM (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 32:62–66CrossRefPubMed

Jocham D, Richter A, Hoffmann L et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599. https://doi.org/10.1016/S0140-6736(04)15590-6 CrossRefPubMed

May M, Brookman-May S, Hoschke B et al (2010) 10-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 59:687–695. https://doi.org/10.1007/s00262-009-0784-6 CrossRefPubMed

10.

Hoover HC, Brandhorst JS, Peters LC et al (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399. https://doi.org/10.1200/JCO.1993.11.3.390 CrossRefPubMed

11.

Berd D, Sato T, Maguire HC et al (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415. https://doi.org/10.1200/JCO.2004.06.043 CrossRefPubMed

12.

Simons JW, Mikhak B, Chang JF et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160–5168PubMed

13.

Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350. https://doi.org/10.1016/S0140-6736(98)07186-4 CrossRefPubMed

14.

Baars A, Claessen AM, van den Eertwegh AJ et al (2000) Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol Off J Eur Soc Med Oncol 11:965–970CrossRef

15.

Baars A, Claessen AME, Wagstaff J et al (2002) A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230–1234. https://doi.org/10.1038/sj.bjc.6600254 CrossRefPubMedPubMedCentral

16.

Krieg AM (2012) CpG still rocks! update on an accidental drug. Nucleic Acid Ther 22:77–89. https://doi.org/10.1089/nat.2012.0340 CrossRefPubMed

17.

Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161–167. https://doi.org/10.1038/sj.onc.1210911 CrossRefPubMed

18.

Halperin SA, Van Nest G, Smith B et al (2003) A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461–2467CrossRefPubMed

19.

Ellis RD, Martin LB, Shaffer D et al (2010) Phase 1 trial of the plasmodium falciparum blood stage vaccine MSP142-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS One 5:e8787. https://doi.org/10.1371/journal.pone.0008787 CrossRefPubMedPubMedCentral

20.

Speiser DE, Liénard D, Rufer N et al (2005) Rapid and strong human CD8⁺ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739–746. https://doi.org/10.1172/JCI23373 CrossRefPubMedPubMedCentral

21.

Speiser DE, Schwarz K, Baumgaertner P et al (2010) Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 33:848–858. https://doi.org/10.1097/CJI.0b013e3181f1d614 CrossRefPubMed

22.

Karbach J, Gnjatic S, Bender A et al (2009) Tumor-reactive CD8⁺ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide® ISA-51: Association with survival. Int J Cancer 126:NA-NA. https://doi.org/10.1002/ijc.24850 CrossRef

23.

Karbach J, Neumann A, Atmaca A et al (2011) Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res 17:861–870. https://doi.org/10.1158/1078-0432.CCR-10-1811 CrossRefPubMed

24.

Peters LC, Brandhorst JS, Hanna MG (1979) Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353–1360PubMed

25.

Molenkamp BG, Sluijter BJR, van Leeuwen PAM et al (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8⁺ T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532–4542. https://doi.org/10.1158/1078-0432.CCR-07-4711 CrossRefPubMed

26.

Sallusto F, Lenig D, Förster R et al (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708–712. https://doi.org/10.1038/44385 CrossRefPubMed

27.

Allan SE, Crome SQ, Crellin NK et al (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354. https://doi.org/10.1093/intimm/dxm014 CrossRefPubMed

28.

Wang J, Ioan-Facsinay A, van†„der†„Voort EIH et al (2007) Transient expression of FOXP3 in human activated nonregulatory CD4⁺ T cells. Eur J Immunol 37:129–138. https://doi.org/10.1002/eji.200636435 CrossRefPubMed

29.

Gavin MA, Torgerson TR, Houston E et al (2006) Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103:6659–6664. https://doi.org/10.1073/pnas.0509484103 CrossRefPubMedPubMedCentral

30.

Huijts CM, Santegoets SJ, de Jong TD et al (2017) Immunological effects of everolimus in patients with metastatic renal cell cancer. Int J Immunopathol Pharmacol 30:341–352. https://doi.org/10.1177/0394632017734459 CrossRefPubMedPubMedCentral

31.

Dzionek A (2001) BDCA-2, a Novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194:1823–1834. https://doi.org/10.1084/jem.194.12.1823 CrossRefPubMedPubMedCentral

32.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM et al (2017) Transcriptional profiling reveals functional dichotomy between human slan + non-classical monocytes and myeloid dendritic cells. J Leukoc Biol 102:1055–1068. https://doi.org/10.1189/jlb.3MA0117-037R CrossRefPubMed

33.

Schäkel K, Mayer E, Federle C, et al (1998) A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 28:4084–4093. https://doi.org/10.1002/(SICI)1521-4141(199812)28:12%3C4084::AID-IMMU4084%3E3.0.CO;2-4 CrossRefPubMed

34.

Schäkel K, Kannagi R, Kniep B et al (2002) 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17:289–301CrossRefPubMed

35.

van Cruijsen H, van der Veldt AAM, Vroling L et al (2008) Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14:5884–5892. https://doi.org/10.1158/1078-0432.CCR-08-0656 CrossRefPubMed

36.

Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor–based antitumor vaccine. J Clin Oncol 25:2546–2553. https://doi.org/10.1200/JCO.2006.08.5829 CrossRefPubMed

37.

Santegoets SJ, Stam AG, Lougheed SM et al (2014) Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother cancer 2:31. https://doi.org/10.1186/s40425-014-0031-3 CrossRefPubMedPubMedCentral

38.

Sokal JE (1975) Measurement of delayed skin-test responses. N Engl J Med 293:501–502. https://doi.org/10.1056/NEJM197509042931013 CrossRefPubMed

39.

Baars A, Claessen A, Wagstaff J et al (2002) A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:1230–1234. https://doi.org/10.1038/sj/bjc/6600254 CrossRefPubMedPubMedCentral

40.

Harris RC, Chianese-Bullock KA, Petroni GR et al (2012) The vaccine-site microenvironment induced by injection of incomplete freundʼs adjuvant, with or without melanoma peptides. J Immunother 35:78–88. https://doi.org/10.1097/CJI.0b013e31823731a4 CrossRefPubMedPubMedCentral

41.

Hailemichael Y, Dai Z, Jaffarzad N et al (2013) Persistent antigen at vaccination sites induces tumor-specific CD8 + T cell sequestration, dysfunction and deletion. Nat Med 19:465–472. https://doi.org/10.1038/nm.3105 CrossRefPubMedPubMedCentral

42.

Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157. https://doi.org/10.1158/1078-0432.CCR-08-1332 CrossRefPubMed

43.

Draghiciu O, Nijman HW, Hoogeboom BN et al (2015) Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 4:e989764. https://doi.org/10.4161/2162402X.2014.989764 CrossRefPubMedPubMedCentral

44.

Farsaci B, Donahue RN, Coplin MA et al (2014) Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2:1090–1102. https://doi.org/10.1158/2326-6066.CIR-14-0076 CrossRefPubMedPubMedCentral

45.

Rini BI, Stenzl A, Zdrojowy R et al (2016) IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17:1599–1611. https://doi.org/10.1016/S1470-2045(16)30408-9 CrossRefPubMed

46.

Finke JH, Rini B, Ireland J et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674–6682. https://doi.org/10.1158/1078-0432.CCR-07-5212 CrossRefPubMed

47.

Ko JS, Rayman P, Ireland J et al (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526–3536. https://doi.org/10.1158/0008-5472.CAN-09-3278 CrossRefPubMedPubMedCentral

48.

Gros A, Parkhurst MR, Tran E et al (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22:433–438. https://doi.org/10.1038/nm.4051 CrossRefPubMedPubMedCentral

49.

McGranahan N, Furness AJS, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. https://doi.org/10.1126/science.aaf1490 CrossRefPubMedPubMedCentral

50.

Höltl L, Rieser C, Papesh C et al (1998) CD83 + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 352:1358CrossRefPubMed

51.

Wierecky J, Müller MR, Wirths S et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910–5918. https://doi.org/10.1158/0008-5472.CAN-05-3905 CrossRefPubMed

52.

Walter S, Weinschenk T, Stenzl A et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261. https://doi.org/10.1038/nm.2883 CrossRefPubMed

53.

Rittig SM, Haentschel M, Weimer KJ et al (2011) Intradermal vaccinations with RNA coding for TAA generate CD8 + and CD4 + immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19:990–999. https://doi.org/10.1038/mt.2010.289 CrossRefPubMed

Title: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
Authors: Bas D. Koster
Saskia J. A. M. Santegoets
Jorien Harting
Arnold Baars
S. Marieke van Ham
Rik J. Scheper
Erik Hooijberg
Tanja D. de Gruijl
Alfons J. M. van den Eertwegh
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Kidney Cancer
Vaccination
Kidney Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 6/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02320-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2019

Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series

Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy

Systemic and local immunosuppression in patients with high-grade meningiomas

DNA lesions correlate with lymphocyte function after selective internal radiotherapy

Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile

Keynote webinar | Spotlight on antibody–drug conjugates in cancer